Extramedullary manifestations of acute myeloid leukemia (AML) occur in approximately 2.5-9.1% of cases at diagnosis and can also present during relapse [1] and are associated with chromosomal abnormalities such as t(8;21) and inv(16), as well as specific cell surface markers in flow cytometry (CD56, CD2, CD4, CD7) and certain AML subtypes (M2, M4, M5) [1,2]. This evidence concerns the gene CD7 and acute myeloid leukemia.